Disc Medicine: Achieving Functional Endpoint More Important [Seeking Alpha]
Disc Medicine, Inc. (IRON)
Company Research
Source: Seeking Alpha
Play 8min Summary Disc Medicine's lead molecule, bitopertin, failed to meet key functional endpoints in phase 2 trials for Erythropoietic Porphyrias, causing a significant drop in stock price. Despite reducing protoporphyrin IX levels, bitopertin did not improve sunlight tolerance, making it ineffective for EPP patients. With a market cap of $1.49bn and $500mn in cash, Disc Medicine has a cash runway of over 10 quarters but faces high risks. Given the failure of bitopertin in its lead indication, I am not interested in investing in Disc Medicine stock at this time. Pgiam/iStock via Getty Images In my August 2023 article on Disc Medicine ( NASDAQ: IRON ), I said that while Disc is targeting a small indication with a Roche-rejected molecule called bitopertin, their valuation seems just 4-5x their peak revenue potential. I thought we could live with that, and suggested a small pilot. The stock did go up nicely after that, but some not-so-rosy data from their phase 2 prog
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at HC Wainwright from $70.00 to $118.00. They now have a "buy" rating on the stock.MarketBeat
- Disc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswire
- Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock, up previously from $75.00.MarketBeat
- Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. [Yahoo! Finance]Yahoo! Finance
IRON
Earnings
- 11/12/24 - Beat
IRON
Sec Filings
- 11/20/24 - Form EFFECT
- 11/19/24 - Form 4
- 11/15/24 - Form 424B5
- IRON's page on the SEC website